The STAGED-PKD 2-Stage Adaptive Study With a Patient Enrichment Strategy and Treatment Effect Modeling for Improved Study Design Efficiency in Patients With ADPKD

Gabow, 1993, Autosomal dominant polycystic kidney disease, N Engl J Med, 329, 332, 10.1056/NEJM199307293290508 Grantham, 2016, The importance of total kidney volume in evaluating progression of polycystic kidney disease, Nat Rev Nephrol, 12, 667, 10.1038/nrneph.2016.135 Merrill, 2011, Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics, Chem Rev, 111, 6387, 10.1021/cr2002917 Natoli, 2020, Glycosphingolipid metabolism and polycystic kidney disease, Cell Signal, 69, 10.1016/j.cellsig.2020.109526 Peterschmitt, 2021, Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers, Clin Pharmacol Drug Dev, 10, 86, 10.1002/cpdd.865 Smith, 2019, Addressing the need for clinical trial end points in autosomal dominant polycystic kidney disease: a report from the polycystic kidney disease outcomes consortium (PKDOC), Am J Kidney Dis, 73, 533, 10.1053/j.ajkd.2018.11.001 Irazabal, 2015, Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials, J Am Soc Nephrol, 26, 160, 10.1681/ASN.2013101138 Yu, 2019, Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease, Kidney Int, 95, 1253, 10.1016/j.kint.2018.12.023 Bae, 2019, Growth pattern of kidney cyst number and volume in autosomal dominant polycystic kidney disease, Clin J Am Soc Nephrol, 14, 823, 10.2215/CJN.10360818 Chapman, 2012, Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease, Clin J Am Soc Nephrol, 7, 479, 10.2215/CJN.09500911 Grantham, 2006, Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes, Clin J Am Soc Nephrol, 1, 148, 10.2215/CJN.00330705 Schrier, 2014, Blood pressure in early autosomal dominant polycystic kidney disease, N Engl J Med, 371, 2255, 10.1056/NEJMoa1402685 Torres, 2014, Angiotensin blockade in late autosomal dominant polycystic kidney disease, N Engl J Med, 371, 2267, 10.1056/NEJMoa1402686 Torres, 2012, Tolvaptan in patients with autosomal dominant polycystic kidney disease, N Engl J Med, 367, 2407, 10.1056/NEJMoa1205511 Torres, 2017, Tolvaptan in later-stage autosomal dominant polycystic kidney disease, N Engl J Med, 377, 1930, 10.1056/NEJMoa1710030 Perrone, 2020, The NOCTURNE randomized trial comparing 2 tolvaptan formulations, Kidney Int Rep, 5, 801, 10.1016/j.ekir.2020.03.011 Ku, 2016, Change in measured GFR versus eGFR and CKD outcomes, J Am Soc Nephrol, 27, 2196, 10.1681/ASN.2015040341 Levey, 2020, Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration with the US food and drug administration and european medicines agency, Am J Kidney Dis, 75, 84, 10.1053/j.ajkd.2019.06.009 Natoli, 2010, Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models, Nat Med, 16, 788, 10.1038/nm.2171 Chapman, 2007, Autosomal dominant polycystic kidney disease: time for a change?, J Am Soc Nephrol, 18, 1399, 10.1681/ASN.2007020155 Bretz, 2009, A graphical approach to sequentially rejective multiple test procedures, Stat Med, 28, 586, 10.1002/sim.3495 Irazabal, 2016, Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial, Kidney Int Rep, 1, 213, 10.1016/j.ekir.2016.08.001 Caroli, 2013, Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial, Lancet, 382, 1485, 10.1016/S0140-6736(13)61407-5 Meijer, 2018, Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: the DIPAK 1 randomized clinical trial, JAMA, 320, 2010, 10.1001/jama.2018.15870 Perico, 2019, Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): a randomized, double-blind, placebo-controlled, multicenter trial, PLoS Med, 16, 10.1371/journal.pmed.1002777 Chow, 2015, Analysis of two-stage adaptive seamless trial design, Pharm Anal Acta, 6 Barnawi, 2018, Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment, Int J Nephrol Renovasc Dis, 11, 53, 10.2147/IJNRD.S136359